胰腺癌：KOL 的觀點

本報告分析了全球胰腺癌 (PC) 治療藥物市場的概況，包括疾病概況、主要治療方法、概況 我們將匯總並發布 KOL（行業專家）的意見等信息市場走向。

內容

執行摘要

胰腺癌 (PC) 當前和未來的治療方案

研究目的

批准的藥物

• 免疫療法
  • Keytruda（pembrolizumab，默克公司）
  • Lynparza（奧拉帕尼，阿斯利康）

後期管線藥物

• 多胺抑製劑
  • Ivospemin（SBP101，Panbela Therapeutics）
• 結締組織生長因子 (CTGF) 抑製劑
  • Pamrevlumab（FibroGen）
• 其他新藥
  • 馬賽替尼（AB Science）
  • GRASPA（Eryaspase，Erytech Pharma）

早期管線藥物 - 抗 PD-1/PD-L1 聯合療法

• Jemperli（dostarlimab，GSK）和 Zejula（niraparib，GSK）
  • 關鍵見解總結
• Opdivo（nivolumab，Bristol Myers Squibb）和聯合療法
• PD-L1 t-haNK (ImmunityBio)□Anktiva (ImmunityBio)
• Letifanlimab（因塞特）Erragussib（9-ING-41，Actuate Therapeutics）

早期管道藥物 - 其他新興療法

• Tedopi（OSE 2101，OSE 免疫療法）
  • 關鍵見解總結
• NIS793□Spartalizumab（諾華）
• Nadunolimab（CAN-04，Cantargia）
• Mitazalimab（Alligator Bioscience）□CDX 1140（Celldex Therapeutics）
• AZD 0171（阿斯利康）
• ABTL 0812（能力製藥）
• Omvansertib（卡迪夫腫瘤科）
• Tem Telquib（禮來公司）

胰腺癌 (PC) 藥物的未來趨勢和機會

• 最終與臨床相關的 PC 免疫檢查點抑製劑：不太可能在未來 3-5 年內實現，但研究人員繼續從各個角度進行實驗
  • 在可預見的未來，化療仍然是 PC 治療的基石，但隨著免疫療法和新型藥物的結合，情況可能會發生變化

附錄

• KOL 詳情
  • 北美的 KOL
  • 歐洲 KOL

While Merck & Co's Keytruda is seen as a 'game changer' for US patients with unresectable or metastatic microsatellite instability-high (MSI-high) or mismatch repair deficient (dMMR) solid tumours, or tumours that have high mutational burden (TMB-high), do KOLs see its potential in larger PC populations? Will Phase III POLO study readouts impact the use of Lynparza? How do KOLs assess the potential of FibroGen's pipeline CTGF inhibitor pamrevlumab? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the Report Highlights slidedeck and the KOL Bulletins via the Attachments area

Table of Contents

Executive summary

Current and future treatment algorithm for PC

Research objectives

Approved drugs

• Immunotherapy
  • Keytruda (pembrolizumab; Merck & Co.)
  • Lynparza (olaparib; AstraZeneca)

Late-stage pipeline drugs

• Polyamine inhibitors
  • Ivospemin (SBP101; Panbela Therapeutics)
• Connective tissue growth factor (CTGF) inhibitors
  • Pamrevlumab (FibroGen)
• Other novel agents
  • Masitinib (AB Science)
  • GRASPA (eryaspase; Erytech Pharma)

Early-stage pipeline drugs - anti-PD-1/PD-L1 combinations

• Jemperli (dostarlimab; GSK) and Zejula (niraparib; GSK)
  • Key insights summary
  • Opdivo (nivolumab; Bristol Myers Squibb) and combinations
  • PD-L1 t-haNK (ImmunityBio) and Anktiva (ImmunityBio)
  • Retifanlimab (Incyte) and elraglusib (9-ING-41; Actuate Therapeutics)

Early-stage pipeline drugs - other novel therapies

• Tedopi (OSE 2101; OSE Immunotherapeutics)
  • Key insights summary
  • NIS793 and spartalizumab (Novartis)
  • Nadunolimab (CAN-04; Cantargia)
  • Mitazalimab (Alligator Bioscience) and CDX 1140 (Celldex Therapeutics)
  • AZD 0171 (AstraZeneca)
  • ABTL 0812 (Ability Pharmaceuticals)
  • Onvansertib (Cardiff Oncology)
  • Temuterkib (Eli Lilly)

Future trends and opportunities in PC treatment

• The holy grail of clinically meaningful efficacy of immune checkpoint inhibitors in PC may not be achievable within the next three to five years, but investigators continue to try all angles
  • Chemotherapy will remain the cornerstone of treatment in PC for the foreseeable future, but with increasing integration of immunotherapy and novel agents

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe